2019 Annual Business Report

The strength of an
integrated business model

img-small

AN INTEGRATED BUSINESS MODEL

Valneva’s integrated business model is based on valuable commercial and R&D assets in important, high-value niches.

R&D
Investments 2019

37.9m
Our vaccine pipeline

Our vaccine pipeline

Valneva is currently developing two unique vaccines addressing two of the fastest growing vector-borne diseases. No vaccines are currently available for these diseases.

Lyme disease – VLA15

Lyme disease – VLA15

Lyme disease is the fastest growing and most feared tick-borne illness in the Northern Hemisphere [1,2]. VLA15 is the only active Lyme disease vaccine program in clinical development today.

Chikungunya  – VLA1553

Chikungunya – VLA1553

Chikungunya is a highly prevalent mosquito-borne infection in tropical and subtropical regions. Our highly differentiated candidate, VLA1553, is the only single-shot vaccine against chikungunya today, aiming for long lasting protection for travelers, military personnel and individuals at risk living in endemic areas.

Wolfgang Bender Chief Medical Officer

In 2019, Valneva delivered product sales revenue of €129.5 million in 2019, mainly from its two marketed travel vaccines IXIARO® and DUKORAL®, representing 25% growth (22% at CER) compared to 2018.

Global Manufacturing Network

Global Manufacturing Network

Valneva’s manufacturing facilities include three in-house operations to cover the internal and external production of clinical and commercial products.

Our Marketing & Distribution Structure

Our Marketing & Distribution Structure

Valneva has a strong, specialized commercial capability for the successful distribution of its travelers’ vaccines in key travel vaccine markets.

Franck GrimaudPresident & Chief Business Officer